Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134758
Status:
UNKNOWN
Last Update Posted:
2009-07-29
First Post:
2005-08-23
Brief Title:
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis FAP Patients
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients URSOPAF
Status:
UNKNOWN
Status Verified Date:
2009-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis FAP patients who had a restorative proctocolectomy Ursodeoxycholic acid UDCA modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation
Detailed Description:
We designed a randomized double blinded study to evaluate the efficiency of UDCA in the treatment of duodenal adenomas One hundred patients are planned to be included Fifty will receive UDCA and fifty a placebo Three duodenoscopies are planned one before inclusion one at the end of the first year of follow-up and one after two years of follow-up at the end of the protocol These duodenoscopies are associated to endoscopies of the ileal reservoir performed at the time of restorative proctocolectomy and are recorded numerically Severity of the duodenal adenomas are evaluated according to the SPIGELMAN score Patients are seen every 6 months Before each endoscopy blood samples are collected for biliary acid profile analysis Moreover during endoscopies duodenal fluid and ileal fluid are collected for biliary acid profile analysis also
At the end of the follow-up of the last patients included nov 2008 biliary acid profile analysis will be performed and statistical analysis of the results will be performed
At the end of the follow-up of the last patients included nov 2008 biliary acid profile analysis will be performed and statistical analysis of the results will be performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AOM 03041 | None | None | None |